// App-Quantinova.ai

3 : NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.

Researchers

Presenter

  • Somnath Mukherjee

Principal Investigators

  • Chris Hurt

  • Sarah Gwynne

  • Andrew Bateman

  • Simon Gollins

  • Ganesh Radhakrishna

  • Jo Canham

  • Ruby Ray

  • Heike I Grabsch

  • Ricky A. Sharma

  • Rhydian Maggs

  • Maria A Hawkins

  • David Sebag-Montefiore

  • Tim Maughan

  • Gareth Griffiths

  • Tom David Lewis Crosby

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • Singleton Hospital, Swansea, United Kingdom

  • University of Southampton Faculty of Medicine, Southampton, United Kingdom

  • North Wales Cancer Treatment Centre, Bodelwyddan, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Wales Cancer Trials Unit, Cardiff University, Cardiff, United Kingdom

  • Maastricht University Medical Center, Maastricht, Netherlands

  • Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom

  • Cardiff NCRI RTTQA Group, Cardiff, United Kingdom

  • St James's Institute of Oncology, St. James's University Hospital, West Yorkshire, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

Locations

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Esophageal Cancer

  • Gastric antral vascular ectasia

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine

  • Carboplatin

  • Oxaliplatin

  • Paclitaxel

  • Capecitabine + Oxaliplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01843829

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved